Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 bln deal
Aug 8 (Reuters) – Pfizer Inc on Monday agreed to pay $5.4 billion in cash for sickle cell disease drugmaker Global Blood Therapeutics (GBT.O), as it looks to capitalize on a surge in revenue from its COVID-19 vaccine and treatment.Pfizer will pay $68.50 per GBT share, which represents a 7.3% premium to its Friday closing …
Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 bln deal Read More »